Interview

#Antibodies #Bispecific Antibodies #Interview #Oncology #Therapeutic Antibodies

Dual-targeted antibody innovations for cancer treatment

David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, speaks to Megan Thomas about innovation in therapeutic antibody development, in the context of the company’s accelerated development of a novel PD1/VEGFR2 bifunctional antibody planned to enter the clinic in 2025, designed as a dual-pathway, single agent, IgG therapy targeting… Read More

#Cancer Research #Exclusive Content

#Absci #AI / data analytics / healthtech / informatics #Antibodies #Artificial intelligence (AI) #Drug discovery #Drug targets #Interview #Machine learning

New podcast: The continued evidence of AI’s drug discovery value

This is the latest episode of the free DDW narrated podcast, titled “The continued evidence of AI’s drug discovery value”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “How generative AI could improve drug discovery” and “Can… Read More

#News

Cancer cell
#CAR-T #Cell therapy #Haematology #Interview #March Biosciences #Oncology

Pushing past the limitations of CAR-T therapies

DDW Editor Reece Armstrong speaks to Sarah Hein, CEO and Co-founder of March Biosciences, about the company’s recent fundraising efforts and its development of CAR-T therapies addressing challenging blood cancers. RA: What are the limitations of current standard-of-care therapies for blood cancers? SH: There are many treatment options for the… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Cancer therapeutics #Cancer treatment #Interview #Oncology

Reducing cancer side effects through targeted therapies

Harry Palmer, Royal Commission of 1851 Industrial Fellow and PhD at University of Strathclyde, shares with DDW’s Megan Thomas how antibody-drug conjugates (ADCs) are revolutionising cancer treatment by offering targeted therapies with improved efficacy and reduced side effects, while addressing challenges in their development and paving the way for future… Read More

#Cancer Research #Exclusive Content

Hepatitis virus
#Gene editing #Genetics / genomics #hepatitis #Interview

Can this gene editing company develop a functional cure for HBV?

DDW Editor Reece Armstrong speaks to Cassie Gorsuch, Vice President, Gene Therapy, at Precision BioSciences about limitations in treating hepatitis B (HBV) and the company’s recent clinical trial application (CTA) approval in Moldova for its lead candidate PBGENE-HBV. RA: What are the limitations of current standard-of-care treatments for HBV? … Read More

#Exclusive Content

#Early access #Interview

Bridging the gap to investigational medicines

DDW Editor Reece Armstrong speaks to Christine MacCracken, Executive Director of Patient Strategies & Solutions at Johnson & Johnson Innovative Medicine, about expanded access strategies and the company’s decision to create a guide to help reduce barriers to investigational medicines for seriously or terminal ill patients. RA: Why are expanded… Read More

#Exclusive Content

Cancer cells
#AstraZeneca #Cancer research #Guide #Immune response #Immuno-oncology #Immunotherapy #Immutep #Interview #Oncology #OncologyCancer research

Podcast: Breakthroughs and opportunities in cancer research

This is the latest episode of the free DDW narrated podcast, titled “Where are the global breakthroughs, opportunities and developments in cancer research?”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Global breakthroughs in cancer drug discovery”, “… Read More

#News

#Drug development #Drug discovery #Interview #Sitting Down With #The Jackson Laboratory #Vodcast

Vodcast: Revolutionising preclinical research with AI-powered home cage monitoring

The latest sponsored DDW Sitting Down With vodcast features Michael Ellis, Senior Director of R&D at The Jackson Laboratory (JAX), and Timothy Robertson, CEO of TLR Ventures and Leader of the Digital In Vivo Alliance to introduce their new digital home cage monitoring system, Envision. Both Ellis and… Read More

#Videos

Cancer cells
#Cancer research #CAR-T #Gene mutation #Genetics / genomics #Immunotherapy #Interview #Mass spectrometry / NMR #Meet the Researcher #Nautilus #Oncology #Precision medicine #Protein chemistry / Proteomics #Rare cancers

Podcast: New ways of looking at effective cancer treatment

This is the latest episode of the free DDW narrated podcast, titled “New ways of looking at effective cancer treatment”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “3D Genomics and targeted cancer therapies”, “Democratising… Read More

#News

#Career #Cell Science #ELRIG #Interview #Meet the Researcher #University of Glasgow

Elaine Duncan: A journey in science and outreach

Earlier this year, Elaine Duncan spoke with DDW’s Diana Spencer in a Meet the Researcher interview. At the European Laboratory Research & Innovation Group (ELRIG)’s annual event, Drug Discovery 2024, she again spoke with DDW and told Megan Thomas about her journey to her current multifaceted role both at… Read More

#Exclusive Content

Immunotherapy
#Cancer Research Institute #Immunotherapy #Interview #Oncology

Why immunotherapy still holds so much potential

Dr Jill O’Donnell Tormey, CEO and Director of Scientific Affairs at the Cancer Research Institute, US, discusses the future of cancer research with DDW’s Megan Thomas. Innovation & opportunity Reflecting on innovation and opportunity in global cancer research, Dr Jill O’Donnell-Tormey recognises modalities like cell therapies, bispecifics, antibody drug conjugates… Read More

#Cancer Research #Exclusive Content

#Career #Gene therapy #Interview #Meet the Researcher

Meet the researcher: Dr Gloria Gonzalez-Aseguinolaza

In July 2024, Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics, received the Rosalind Franklin Society Special Award in Science. DDW’s Diana Spencer caught up with her about her career in gene therapy. DS: Can you tell us what you do and what you’re working on at the moment?… Read More

#Exclusive Content

Antibodies
#Immunotherapy #Interview #Monoclonal antibodies #Oncology #Therapeutic Antibodies

The new wave: Creating next-gen antibody therapies

Diana Spencer speaks to Dr Wansu Qiu, Technical Account Manager at Sino Biological US, about how advances in engineering technologies are paving the way for improved antibody drugs. DS: Since 1986, the FDA has granted marketing authorisation to over 100 therapeutic antibodies, many in oncology. Why has this been a… Read More

#Exclusive Content #Opinion

Therapeutic antibodies
#Bispecific Antibodies #Interview #Lymphoma #Oncology

Q&A: Targeting difficult to treat lymphomas with a bispecific antibody

DDW Editor Reece Armstrong speaks to Tahi Ahmadi, MD, PhD, Executive Vice President & Chief Medical Officer, Head of Experimental Medicines, Genmab & Jacqueline Nielsen, PhD, Therapeutic Head, Hematology, AbbVie, about the recommendation and the development of epcoritamab. Earlier this year, the European Medicines Agenecy’s (EMA) Committee for Medicinal Products… Read More

#Cancer Research #Exclusive Content

RNA
#CRISPR #Gene editing #Genetics / genomics #Interview #RNA #University of Sydney

Beyond CRISPR – what a new tool offers gene editing

DDW Editor Reece Armstrong speaks to Dr Sandro Ataide, Senior Lecturer in Structural Biology at the School of Life and Environmental Sciences Sydney Drug Discovery Initiative (DDI). Earlier this year, Dr Ataide’s team developed a gene-editing tool called SeekRNA that uses a programmable ribonucleic acid (RNA) strand that can… Read More

#Exclusive Content

#Career #Interview #Meet the Researcher #Neurodegenerative disorders

Meet the researcher: Dr Joanne Taylor

DDW’s Megan Thomas looks at a day in the life of Dr Joanne Taylor, Senior Vice President and Head of Discovery Research at Gain Therapeutics. MT: Can you provide a top line summary of your research?  JT: We are developing novel small molecule, disease-modifying, allosteric regulators to treat serious… Read More

#Exclusive Content